No Data
No Data
Shandong Buchang Pharmaceuticals (603858.SH): The subsidiary has once again passed the recognition as a high-tech enterprise.
On May 6, Gelonghui reported that Shandong Buchang Pharmaceuticals (603858.SH) announced that its wholly-owned subsidiary Baoding Tianhao Pharmaceutical Co., Ltd. (hereinafter referred to as "Baoding Tianhao") received the "High-tech Enterprise Certificate" jointly issued by the Hebei Province Department of Industry and Information Technology, the Hebei Province Finance Department, and the State Taxation Administration Hebei Provincial Taxation Bureau. Baoding Tianhao's re-certification as a high-tech enterprise is noted, with certificate number: GR202413001351, issuance date: November 11, 2024, and validity period: three years. The recognition of Baoding Tianhao as a high-tech enterprise marks that Baoding Tianhao has strong innovative research and development capabilities, ...
Shandong Buchang Pharmaceuticals (603858.SH): has cumulatively repurchased 0.6% of its shares.
On May 6, Glonghui reported that Shandong Buchang Pharmaceuticals (603858.SH) announced that as of April 30, 2025, the company has cumulatively repurchased 6,620,630 shares through centralized bidding Trade, accounting for 0.60% of the company's total share capital, with a highest purchase price of 15.07 yuan/share, a lowest price of 13.86 yuan/share, and a total amount paid of 98,037,536.97 yuan (excluding transaction fees).
Shandong Buchang Pharmaceuticals (603858.SH): There are currently no research and development plans for tablet forms of Wuxin granules.
Gelonghui, April 30 – Shandong Buchang Pharmaceuticals (603858.SH) stated on the interactive platform that the company currently has no research and development plans for the tablet form of the stable heart granules.
Shandong Buchang Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Summary of the 2024 Annual Report of Shandong Buchang Pharmaceutical Co., Ltd.
Shandong Buchang Pharmaceutical Co., Ltd. 2024 Annual Report